{"id":7779,"date":"2024-11-18T10:58:36","date_gmt":"2024-11-18T02:58:36","guid":{"rendered":"https:\/\/regask.com\/?p=7779"},"modified":"2024-11-21T17:44:39","modified_gmt":"2024-11-21T09:44:39","slug":"le-mhlw-du-japon-promeut-les-approbations-de-rwd-pharma","status":"publish","type":"post","link":"https:\/\/regask.com\/fr\/japan-mhlw-promotes-rwd-pharma-approvals\/","title":{"rendered":"Le MHLW (Japon) encourage l&#039;utilisation de donn\u00e9es du monde r\u00e9el (RWD) pour\u2026"},"content":{"rendered":"<p>Le 7 octobre 2024, le minist\u00e8re japonais de la Sant\u00e9, du Travail et de la Protection sociale (MHLW) a publi\u00e9 une notification importante encourageant l&#039;utilisation de donn\u00e9es du monde r\u00e9el (RWD) pour soutenir les modifications partielles dans les approbations de produits pharmaceutiques. Cette mise \u00e0 jour, mise en \u00e9vidence dans un article de Pharma Japan, repr\u00e9sente une \u00e9volution strat\u00e9gique vers l&#039;utilisation des donn\u00e9es du registre des patients (couvrant les profils de maladie, les sp\u00e9cificit\u00e9s du traitement et les r\u00e9sultats du suivi) comme une alternative cr\u00e9dible aux essais cliniques traditionnels pour certains changements r\u00e9glementaires. L&#039;initiative souligne l&#039;engagement du MHLW \u00e0 utiliser des preuves du monde r\u00e9el dans les d\u00e9cisions r\u00e9glementaires, am\u00e9liorant ainsi \u00e0 terme l&#039;innovation dans les soins de sant\u00e9 et la gestion du cycle de vie des produits pharmaceutiques.<\/p>\n<p><strong>Points cl\u00e9s de la notification<\/strong><\/p>\n<p>La notification s&#039;adresse aux soci\u00e9t\u00e9s pharmaceutiques qui souhaitent modifier les autorisations de mise sur le march\u00e9 de leurs produits sans n\u00e9cessiter d&#039;essais cliniques \u00e0 grande \u00e9chelle. Ces modifications peuvent inclure des ajustements concernant :<\/p>\n<ul>\n<li><strong>Indications<\/strong>:\u00c9largir ou pr\u00e9ciser les usages th\u00e9rapeutiques.<\/li>\n<li><strong>Dosages<\/strong>:Modifications des doses recommand\u00e9es.<\/li>\n<li><strong>Autres aspects cl\u00e9s<\/strong>:Divers changements importants, tels que d\u00e9finis par le MHLW.<\/li>\n<\/ul>\n<p>Les RWD, qui englobent des donn\u00e9es provenant de sources telles que les dossiers m\u00e9dicaux \u00e9lectroniques (DME), les registres de maladies et de produits, les r\u00e9sultats rapport\u00e9s par les patients et les donn\u00e9es provenant de contextes d&#039;utilisation \u00e0 domicile, fournissent des informations pr\u00e9cieuses issues de contextes cliniques r\u00e9els, offrant un compl\u00e9ment pratique aux essais cliniques traditionnels.<\/p>\n<p><strong>Port\u00e9e et recommandations<\/strong><\/p>\n<p>Bien que les domaines th\u00e9rapeutiques ou les cat\u00e9gories de produits ne soient pas sp\u00e9cifiquement d\u00e9finis, la notification sugg\u00e8re que la politique peut s&#039;appliquer \u00e0 une large gamme de produits pharmaceutiques et m\u00e9dicaux. Il est conseill\u00e9 aux entreprises envisageant d&#039;utiliser des donn\u00e9es de recherche pour leurs demandes r\u00e9glementaires de consulter le MHLW au d\u00e9but du processus pour confirmer que leurs donn\u00e9es r\u00e9pondent aux normes de qualit\u00e9, de pertinence et de fiabilit\u00e9 du MHLW.<\/p>\n<p><strong>Conclusion<\/strong><\/p>\n<p>Cette initiative du MHLW encourage les soci\u00e9t\u00e9s pharmaceutiques japonaises \u00e0 exploiter le RWD comme une ressource r\u00e9glementaire valable, favorisant des adaptations efficaces et bas\u00e9es sur les donn\u00e9es dans le cadre des approbations de produits. Alors que le Japon continue d&#039;adopter des preuves du monde r\u00e9el dans les soins de sant\u00e9, cette approche devrait acc\u00e9l\u00e9rer le processus. <a href=\"https:\/\/regask.com\/fr\/enregistrement-des-ingredients-cosmetiques-au-japon\/\">voie r\u00e9glementaire<\/a> pour des traitements innovants, garantissant un acc\u00e8s rapide \u00e0 des th\u00e9rapies am\u00e9lior\u00e9es.<\/p>\n<hr \/>","protected":false},"excerpt":{"rendered":"<p>Le 7 octobre 2024, le minist\u00e8re japonais de la Sant\u00e9, du Travail et des Affaires sociales (MHLW) a publi\u00e9 une notification importante encourageant l&#039;utilisation des donn\u00e9es en vie r\u00e9elle (RWD) pour appuyer des modifications partielles des autorisations de mise sur le march\u00e9 des m\u00e9dicaments. Cette mise \u00e0 jour, mise en lumi\u00e8re dans un article de Pharma Japan, repr\u00e9sente une initiative strat\u00e9gique visant \u00e0 exploiter les donn\u00e9es des registres de patients, notamment les profils de la maladie, les sp\u00e9cificit\u00e9s du traitement et le suivi.<\/p>","protected":false},"author":43,"featured_media":7847,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[35,519],"tags":[387,496],"class_list":["post-7779","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharma-biotech-latest-insights","category-japan-regulations","tag-real-word-evidence-rwe","tag-market-authorization-regs"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.7 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Japan MHLW Promotes RWD for Pharma Approvals | RegASK<\/title>\n<meta name=\"description\" content=\"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/fr\/le-mhlw-du-japon-promeut-les-approbations-de-rwd-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MHLW (Japan) Encourages Use of Real-World Data (RWD) for Modifications in Pharmaceutical Approvals\" \/>\n<meta property=\"og:description\" content=\"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/fr\/le-mhlw-du-japon-promeut-les-approbations-de-rwd-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-18T02:58:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-21T09:44:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"MHLW (Japan) Encourages Use of Real-World Data (RWD) fo&hellip;\",\"datePublished\":\"2024-11-18T02:58:36+00:00\",\"dateModified\":\"2024-11-21T09:44:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"keywords\":[\"Real-Word-Evidence (RWE)\",\"Market authorization regs\"],\"articleSection\":[\"Pharma and Biotech\",\"Japan\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\",\"name\":\"Japan MHLW Promotes RWD for Pharma Approvals | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"datePublished\":\"2024-11-18T02:58:36+00:00\",\"dateModified\":\"2024-11-21T09:44:39+00:00\",\"description\":\"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/regask.com\\\/japan-mhlw-promotes-rwd-pharma-approvals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png\",\"width\":800,\"height\":600,\"caption\":\"Mhlw Japan Encourages Use Real World Data Rwd Modifications Pharmaceutical Approvals\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Le minist\u00e8re japonais de la Sant\u00e9 et des Services sociaux promeut le RWD pour les approbations pharmaceutiques | RegASK","description":"Le minist\u00e8re japonais de la Sant\u00e9 et des Services sociaux (MHLW) encourage l&#039;utilisation de donn\u00e9es r\u00e9elles pour l&#039;approbation des m\u00e9dicaments, stimulant ainsi l&#039;innovation. Pour en savoir plus, rendez-vous sur RegASK.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/fr\/le-mhlw-du-japon-promeut-les-approbations-de-rwd-pharma\/","og_locale":"fr_FR","og_type":"article","og_title":"MHLW (Japan) Encourages Use of Real-World Data (RWD) for Modifications in Pharmaceutical Approvals","og_description":"Japan\u2019s MHLW encourages use of real-world data for pharma approval, boosting innovation. Read more at RegASK.","og_url":"https:\/\/regask.com\/fr\/le-mhlw-du-japon-promeut-les-approbations-de-rwd-pharma\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2024-11-18T02:58:36+00:00","article_modified_time":"2024-11-21T09:44:39+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#article","isPartOf":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"MHLW (Japan) Encourages Use of Real-World Data (RWD) fo&hellip;","datePublished":"2024-11-18T02:58:36+00:00","dateModified":"2024-11-21T09:44:39+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/"},"wordCount":299,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","keywords":["Real-Word-Evidence (RWE)","Market authorization regs"],"articleSection":["Pharma and Biotech","Japan"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/","url":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/","name":"Le minist\u00e8re japonais de la Sant\u00e9 et des Services sociaux promeut le RWD pour les approbations pharmaceutiques | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","datePublished":"2024-11-18T02:58:36+00:00","dateModified":"2024-11-21T09:44:39+00:00","description":"Le minist\u00e8re japonais de la Sant\u00e9 et des Services sociaux (MHLW) encourage l&#039;utilisation de donn\u00e9es r\u00e9elles pour l&#039;approbation des m\u00e9dicaments, stimulant ainsi l&#039;innovation. Pour en savoir plus, rendez-vous sur RegASK.","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/regask.com\/japan-mhlw-promotes-rwd-pharma-approvals\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2024\/11\/mhlw-japan-encourages-use-real-world-data-rwd-modifications-pharmaceutical-approvals.png","width":800,"height":600,"caption":"Mhlw Japan Encourages Use Real World Data Rwd Modifications Pharmaceutical Approvals"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Le syst\u00e8me d&#039;exploitation d&#039;IA r\u00e9glementaire pour les \u00e9quipes performantes","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/7779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/comments?post=7779"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/posts\/7779\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media\/7847"}],"wp:attachment":[{"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/media?parent=7779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/categories?post=7779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/fr\/wp-json\/wp\/v2\/tags?post=7779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}